As we observe World Cancer Day today, let us look at some of the trends in cancer therapeutics expected to improve cancer ...

The approval was based on results from CodeBreaK 300, a phase 3, multicenter, open-label, randomized trial that enrolled 160 patients who had not had previous treatment with a KRAS G12C inhibitor.

DelveInsight’s, “Metastatic Colorectal Cancer Pipeline Insight” report provides comprehensive insights about 80+ companies ...

also known as sotorasib, will be indicated in the U.S. with Amgen’s (NASDAQ:AMGN) epidermal growth factor receptor (EGFR) inhibitor panitumumab (Vectibix) as a late-line option for KRAS G12C ...

Amgen's first-to-market KRAS inhibitor Lumakras has so far failed ... The US regulator has cleared Lumakras (sotorasib) in combination with Amgen's anti-EGFR antibody Vectibix (panitumumab ...

Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval.

today announced it has exercised early the option to license from GenFleet Therapeutics VS-7375 (also known as GFH375), a potential best-in-class oral and selective KRAS G12D (ON/OFF) inhibitor.

applies to adults whose tumors carry the KRAS G12C mutation. Amgen's treatment pairs Lumakras (sotorasib) with Vectibix (panitumumab), an epidermal growth factor receptor (EGFR) inhibitor ...

The decision, announced Thursday, applies to adults whose tumors carry the KRAS G12C mutation. Amgen's treatment pairs Lumakras (sotorasib) with Vectibix (panitumumab), an epidermal growth factor ...